Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2017 May 3;16(7):1389–1400. doi: 10.1158/1535-7163.MCT-17-0111

Figure 6. Proposed mechanisms of interaction between AR antagonists, HER2 therapeutic antibody, and mTOR inhibitor.

Figure 6

The cross-regulation in breast cancer cells between the HER2/HER3 signaling axis, mTOR integration, and AR is depicted. (A) The feedback and regulatory loops in the normal state are depicted. (B) The effect on these feedback loops when they are therapeutically inhibited is depicted.